GW Pharmaceuticals clinical trials indicate CBD helps Schizophrenia
GW Pharmaceuticals are probably best known for their Sativex medical cannabis oral spray, a whole-plant extract containing THC and CBD which is licensed for use in Multiple Sclerosis. GW Pharmaceuticals have announced some significant mid-trial success for a CBD-dominant medicine when it was given to a group of Schizophrenia patients. The detailed findings were not released at this stage of the trials, though they will be later. GW said that cannabidiol (CBD) consistently outperformed the placebo, and that the proportion of responders was also higher in the active treatment group. This all suggests that CBD has future uses for treatment of Schizophrenia patients assuming that future medical trials continue to show good results.